Evidence map›Paper›PMID 27878439›Full record

SynthesisJournal of neurology2017

Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis.

Maria Kosmidou, Aristeidis H Katsanos, Konstantinos H Katsanos, Athanassios P Kyritsis, Georgios Tsivgoulis, Dimitrios Christodoulou, Sotirios Giannopoulos

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 4 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 4 syntheses or guidelines pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Maria KosmidouFirst Division of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Aristeidis H KatsanosDepartment of Neurology, School of Medicine, University of Ioannina, University Campus, 45110, Ioannina, Greece.
Konstantinos H KatsanosHepatoGastroenterology Unit, School of Medicine, University of Ioannina, Ioannina, Greece.
Athanassios P KyritsisDepartment of Neurology, School of Medicine, University of Ioannina, University Campus, 45110, Ioannina, Greece.
Georgios TsivgoulisSecond Department of Neurology, School of Medicine, University of Athens, Athens, Greece.
Dimitrios ChristodoulouHepatoGastroenterology Unit, School of Medicine, University of Ioannina, Ioannina, Greece.
Sotirios GiannopoulosDepartment of Neurology, School of Medicine, University of Ioannina, University Campus, 45110, Ioannina, Greece. sgiannop@uoi.gr.ORCID http://orcid.org/0000-0001-7443-5179
University of Ioannina · GRUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The association between multiple sclerosis (MS) and inflammatory bowel disease (IBD) has been suggested, apart from their common epidemiological and immunological patterns, also due to observations of increased incidence of both IBD among MS patients and MS among IBD patients. We estimated the risk of concurrent IBD and MS comorbidity, using data from all available case-control studies. We calculated the corresponding Risk ratios (RRs) in each included case-control study to express the risk of IBD and MS concurrence at a given population. We performed additional subgroup analyses according to the type of registry from which the data of the cases were exported (IBD or MS registry) and the IBD type (Crohn's disease, CD or Ulcerative colitis, UC). We included 10 studies, comprising a total of 1,086,430 patients (0.08% of them with concurrent IBD and MS). Pooled RR for IBD/MS comorbitity was 1.54 (95% CI 1.40-1.67; p < 0.0001) with no differences (p = 0.91) among IBD and MS registries (RR 1.53, 95% CI 1.36-1.72, p < 0.001 for MS comorbidity in IBD patients vs. RR 1.55, 95% CI 1.32-1.81, p < 0.001 for IBD comorbidity in MS patients). No difference was also found on the risk of MS comorbidity among patients with CD or UC (RR 1.52, 95% CI 1.34-1.72, p < 0.001 vs. RR 1.55, 95% CI 1.38-1.74, p < 0.001; p for subgroup differences: 0.84). In all analyses no evidence of heterogeneity or publication bias was detected. Both IBD and MS patients seem to have a fifty-percent increased risk of MS or IBD comorbidity, respectively, with no apparent differences between patients with CD or UC.

Indexed as

ComorbidityHumansInflammatory Bowel DiseasesMultiple SclerosisCo-existenceCrohn’s diseaseDemyelinationInflammatory bowel diseasesMultiple sclerosisUlcerative colitis

Identifiers

PMID27878439
OpenAlexW2555359101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.